NRx Pharmaceuticals eyes first commercial revenue in 2024, announces breakthroughs in bi-annual milestone update

Michigan, United States, April 29th, 2024, FinanceWire NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and […]